Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.55 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | F7 | P08709 | 1/20 | 0.53 |
| ▸ | F3 | P13726 | 1/20 | 0.53 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3248999 | 0.84 | HDAC1 (0.62) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL155299 | 0.84 | HDAC1 (0.62) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL10406166 | 0.82 | HDAC1 (0.61) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL5361880 | 0.80 | HDAC1 (0.74) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL2000041 | 0.80 | HDAC1 (0.74) | HDAC1HDAC6THRBLMNAHIF1A | |
| Nicoxamat SCHEMBL93839 | 0.79 | HDAC1 (1.00) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL19593551 | 0.77 | THRB (0.68) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL4469337 | 0.77 | NPC1 (0.71) | HDAC1HDAC6LMNAALDH1A1GAA | |
| SCHEMBL8162429 | 0.77 | HDAC1 (0.69) | HDAC1HDAC6THRBLMNAHIF1A | |
| SCHEMBL8704315 | 0.77 | HDAC1 (0.69) | HDAC1HDAC6THRBLMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5981500-A | Antiparasitic agents related to the milbemycins and avermectins | PFIZER INC. (US) | 1999-11-09 | — | — | US | claimed |
| EP-0677054-B1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0677054-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER INC. (US) | 1995-10-18 | — | — | EP | claimed |
| WO-1994015944-A1 | NEW ANTIPARASITIC AGENTS RELATED TO THE MILBEMYCINS AND AVERMECTINS | PFIZER LIMITED (GB) | 1994-07-21 | — | — | WO | claimed |
| US-10723731-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2018-07-05 | — | — | US | disclosed |
| US-9902724-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| EP-3153180-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M Innovative Properties Company (US) | 2017-04-12 | — | — | EP | disclosed |
| US-20170037045-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY | 2017-02-09 | — | — | US | disclosed |
| US-9475804-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-10-25 | — | — | US | disclosed |
| EP-2717919-B1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES CO (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2861262-A1 | ANTI-CD70 ANTIBODY DRUG CONJUGATES | Ambrx, Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | HORIKOSHI, HIROYOSHI (CA) | 2013-06-27 | — | — | US | disclosed |
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012167088-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-06 | — | — | WO | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723731-B2 | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom | IL2, ICOS, CD40 | HDAC1 2273/4885HDAC6 1538/4885THRB 1969/4885 |
| US-20170037045-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | HDAC1 2273/4885HDAC6 1538/4885THRB 1969/4885 |
| US-20180186792-A1 | HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM | IL2, ICOS, CD40 | HDAC1 2273/4885HDAC6 1538/4885THRB 1969/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | HDAC1 90/4885HDAC6 505/4885THRB 1918/4885 |
| US-20130165446-A1 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE | PPARG, PPARA, PPARD | HDAC1 126/4885HDAC6 354/4885THRB 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.